We are live on ! Find out more

INmune Bio

INMB

Market cap $64.7M

2.33 USD

+0.11

4.95%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

2.35

+0.02

0.86%

1 day

4.95%

5 days

-4.51%

1 month

7.37%

3 months

82.03%

6 months

72.59%

Year to date

51.3%

1 year

18.27%

5 years

-86.79%

10 years

-70.84%

About: INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Employees: 21

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 13.3%

Neutral 86.7%

Negative 0%

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced the appointments of R.

INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept.

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market cap. Ebstrocel offers systemic itch reduction, differentiating it from competitors like KRYS's Vyjuvek, and is positioned for UK, EU, and US regulatory filings by early 2027. Regulatory milestones may include upcoming filings for approval, and the initiation of a confirmatory Phase 3 trial.

INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio Inc. (INMB) Q2 2026 Earnings Call Transcript

INmune Bio Q2 Earnings Call Highlights

INmune Bio NASDAQ: INMB outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027.

INmune Bio Q2 Earnings Call Highlights

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash used in operating activities during the quarter. The rebates strengthen the Company's balance sheet and extend its cash runway as INmune Bio advances CORDStrom™ (Ebstrocel™) toward regulatory filings.

INmune Bio Receives R&D Rebates of Approximately $4.6 Million

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities

INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform.

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

See News Rankings

Price charts implemented using Lightweight Charts™